1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Athos Therapeutics Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) ATH-063, Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | Athos Therapeutics Inc | 120 | 2026-04-30 | 2026-09-21 |
| Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects ATH-063, Placebo - Inflammatory Bowel Diseases, Crohn Disease | Phase 1 | Completed | Athos Therapeutics Inc | 76 | 2023-04-06 | 2024-05-03 |
Autoimmune Diseases (2) · Colitis, Ulcerative (2) · Inflammatory Bowel Diseases (2) · Colitis (1) · Crohn Disease (1) · Ulcer (1)
Australia (1) · United States (1)
David T. Rubin, MD (1) · Nicholas Farinola, B.Sc (Biomed. Sci.),BMBS,FRACP (1)